A Pharmacokinetic Study of an Ibuprofen Topical Patch in Healthy Male and Female Adult Volunteers. Issue 7 (11th January 2018)

• Record Type: Journal Article
• Authors: Lewis, Fraser; Connolly, Mark P.; Bhatt, Aomesh
• Is Part Of: Clinical pharmacology in drug development. Volume 7:Issue 7(2018)
• Page Start: 684
• Page End: 691
• Publication Date: 2018-01-11
• Subjects: Ibuprofen -- topical patch -- pharmacokinetics -- steady state -- pain; Drugs -- Testing -- Periodicals; Drug development -- Periodicals; Clinical pharmacology -- Periodicals; 615.580724
• DOI: 10.1002/cpdd.423
• Languages: English
• ISSNs: 2160-7648

Abstract

Abstract: The pharmacokinetics of a novel locally applied ibuprofen topical patch was evaluated. Healthy subjects (n = 28) were administered a 200‐mg ibuprofen patch every 24 hours for 5 days, and steady‐state pharmacokinetics was determined. The amount of ibuprofen remaining in the patch following each patch removal was also assessed. The maximum steady‐state drug concentration and area under the concentration curve from time 0 on day 5 (t = 0) to the 24‐hours sample on day 6 were 514 ng/mL (95% CI 439 to 603 ng/mL) and 9.78 kg·h/mL (95% CI 8.43 to 11.4 kg·h/mL), respectively. Maximum ibuprofen concentration on day 5 occurred at 20 hours post–patch application. No evidence of drug accumulation was observed, and steady state was achieved between days 2 and 5. Ibuprofen levels attenuated rapidly to baseline within 24 hours after treatment discontinuation. The amount of ibuprofen remaining in the patch was high (≥80%). Treatment‐emergent adverse events were generally mild, with the most prevalent being headache (n = 6; 21.4%). Only 4 TEAEs were considered related to the ibuprofen patch: paresthesia (n = 1), headache (n = 2), and pruritic rash (n = 1). The study found that the systematic absorption of ibuprofen from a 200‐mg patch was low and that the levels of ibuprofen leaving the patch over a 24‐hour period are consistent with levels required for therapeutic relief as shown in other studies.